Topic: autoimmune disease
A phase 2 win for its lead drug in myasthenia gravis has Ra Pharma pressing the button on a $115 million public funding round.
Principia has started a phase 3 program for its BTK inhibitor in the autoimmune disease pemphigus after hitting the target in a midstage trial.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.
Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.
J&J picked up the rights to the CD28 antagonist for €10 million upfront in 2016, but clinical progress stalled following the deal.
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
After having invested in Morphic Therapeutic’s A and B rounds, AbbVie is pulling the trigger on an R&D deal.
Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.